Clinical trials

Clinical trials are research studies that test drug therapies on human participants who have agreed to be involved.

When a potential drug therapy is tested in the laboratory and yields promising results, it moves to clinical trial in order to determine if the therapy is safe and effective enough to be made widely available to the Canadian population. There are different stages of clinical trial that a drug must move through. The final step is approval by Health Canada.

ALS clinical trials usually involve testing potential therapies that aim to either slow the progression of the disease or improve management of symptoms — or they are observational, to learn more about the disease. In many cases, people who participate in clinical trials will not experience the benefits of the therapy, but their generous involvement will help to find a therapy for people who will be diagnosed in the future. One day, a clinical trial will test a therapeutic that slows progression of ALS and those participants might directly benefit from taking part. Learn more in our Clinical Trials FAQs.

For more information, please speak with your clinician (preferably at an ALS clinic) and visit ClinicalTrials.gov, where all legitimate, recognized ALS clinical trials are registered globally. You can also visit the EU Clinical Trials Register and the World Health Organization International Clinical Trials Registry for additional information on clinical trials.

Current Clinical Trials for ALS in Canada

Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation

Sponsor: Neuraltus Pharmaceuticals Inc.
Phase: 2
Status: Recruiting
Sites: Montreal (MNI)
Learn More and Contact

MRI Biomarkers in ALS

Sponsor: University of Alberta
Observational Study
Status: Recruiting
Sites: Calgary, Edmonton, Vancouver, Toronto, Montreal (MNI)
Learn More and Contact

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) (ARTFL)

Sponsor: University of California
Observational Study
Status: Recruiting
Sites: Vancouver, Toronto
Learn More and Contact

Diagnosing Frontotemporal Lobar Degeneration

Sponsor: University Health Network, University of Toronto
Observational Study
Status: Recruiting
Site: Toronto Western Hospital
Learn More and Contact

Phenotype, Genotype & Biomarkers in ALS and Related Disorders

Sponsor: University of Miami
Observational Study
Status: Recruiting
Site: Edmonton
Learn More and Contact

Single and Multiple Dose Study of BIIB067 (Isis-SOD1Rx) in Adults With Amyotrophic Lateral Sclerosis (ALS)

Sponsor: Biogen
Phase: 1
Status: Recruiting
Sites: Toronto, Montreal (MNI) (note – only for individuals with SOD1 mutation)
Learn More and Contact

Methodology Study of Novel Outcome Measures to Assess Progression of ALS

Sponsor: Biogen
Observational Study
Status: Recruiting
Sites: Toronto, Montreal (MNI)
Learn More and Contact

Study of iVAPS mode in Non-invasive Ventilation of ALS

Sponsor: Marta Kaminska
Status: Recruiting
Site: Montreal
Learn More and Contact

A Registry-Based Clinical Trial of Pimozide in Patients With Neuromuscular Junction Transmission Dysfunction Due to ALS

Sponsor: University of Calgary
Phase: 2
Status: Active and no longer recruiting
Sites: Calgary
Learn More and Contact

Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year (VITALITY-ALS)

Sponsor: Cytokinetics
Phase: 3
Status: Active and no longer recruiting
Sites: Calgary, Edmonton, London, Hamilton, Toronto, Montreal (MNI & CHUM), Quebec City, Halifax, Fredricton
Learn More and Contact